complement terminal complex tcc Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Hycult Biotech tcc, human, mab ae11, fitc
    Tcc, Human, Mab Ae11, Fitc, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tcc, human, mab ae11, fitc/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    tcc, human, mab ae11, fitc - by Bioz Stars, 2024-06
    93/100 stars
      Buy from Supplier

    92
    Cusabio mouse terminal complement complex c5b 9 elisa kit
    <t>C5b-9</t> levels of all mice administered with LMWCS-S-O and CS-P. The L-LMWCS-S-O, M-LMWCS-S-O and H-LMWCS-S-O groups were administered with 50, 150 and 450 mg/kg of LMWCS-S-O, respectively. The CS-P group was administered with 150 mg/kg of CS-P. The sham and model groups were administered with saline. Bar graphs present n ≥ 5. * p < 0.05 vs. the model; # p < 0.05 vs. the model.
    Mouse Terminal Complement Complex C5b 9 Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse terminal complement complex c5b 9 elisa kit/product/Cusabio
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse terminal complement complex c5b 9 elisa kit - by Bioz Stars, 2024-06
    92/100 stars
      Buy from Supplier

    92
    Cusabio troponin i tni
    <t>C5b-9</t> levels of all mice administered with LMWCS-S-O and CS-P. The L-LMWCS-S-O, M-LMWCS-S-O and H-LMWCS-S-O groups were administered with 50, 150 and 450 mg/kg of LMWCS-S-O, respectively. The CS-P group was administered with 150 mg/kg of CS-P. The sham and model groups were administered with saline. Bar graphs present n ≥ 5. * p < 0.05 vs. the model; # p < 0.05 vs. the model.
    Troponin I Tni, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/troponin i tni/product/Cusabio
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    troponin i tni - by Bioz Stars, 2024-06
    92/100 stars
      Buy from Supplier

    86
    Thermo Fisher terminal complement complexes tcc
    Direct and sandwich ELISA to <t>determine</t> <t>mAb</t> binding to human, monkey, rat and mouse C7. (A) Direct ELISA: plates were coated with human, monkey (cyno), rat or mouse C7; mAbs were tested in a dilution series (0–10 µg/ml). The graph shows representative binding with the 10 µg/ml capture. (B) Sandwich ELISA: the new mAbs were paired as capture and detect with human C7 used in a dilution series (0–5 µg/ml). The graph shows representative binding with 5 µg/ml C7. As a positive control, polyclonal anti-C7 (goat anti-C7) was used as capture with each of the mAb as detect; rat C7 captured on goat anti-C7 (goat anti-C7; rat C7) was also tested with the mAb as detect. (C) Sandwich ELISA to detect pre-formed <t>TCC</t> in activated NHS; TCC in activated NHS (and NRS for 2H2) was captured on aE11 anti-C9 and the novel mAbs and the positive control E2 anti-C8 mAb used to detect the TCC complex captured. (D) TCC complexes generated in NHS (or NRS for 2H2) in the presence of each of the new mAb (biotinylated) were captured on avidin-coated plates, then polyclonal antibodies against each of the terminal complement proteins used to test the presence of the respective components in the complex. The error bars are standard errors of triplicates. All experiments were repeated three times with the same results.
    Terminal Complement Complexes Tcc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/terminal complement complexes tcc/product/Thermo Fisher
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    terminal complement complexes tcc - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    86
    Diatec Inc terminal complement complex tcc
    Direct and sandwich ELISA to <t>determine</t> <t>mAb</t> binding to human, monkey, rat and mouse C7. (A) Direct ELISA: plates were coated with human, monkey (cyno), rat or mouse C7; mAbs were tested in a dilution series (0–10 µg/ml). The graph shows representative binding with the 10 µg/ml capture. (B) Sandwich ELISA: the new mAbs were paired as capture and detect with human C7 used in a dilution series (0–5 µg/ml). The graph shows representative binding with 5 µg/ml C7. As a positive control, polyclonal anti-C7 (goat anti-C7) was used as capture with each of the mAb as detect; rat C7 captured on goat anti-C7 (goat anti-C7; rat C7) was also tested with the mAb as detect. (C) Sandwich ELISA to detect pre-formed <t>TCC</t> in activated NHS; TCC in activated NHS (and NRS for 2H2) was captured on aE11 anti-C9 and the novel mAbs and the positive control E2 anti-C8 mAb used to detect the TCC complex captured. (D) TCC complexes generated in NHS (or NRS for 2H2) in the presence of each of the new mAb (biotinylated) were captured on avidin-coated plates, then polyclonal antibodies against each of the terminal complement proteins used to test the presence of the respective components in the complex. The error bars are standard errors of triplicates. All experiments were repeated three times with the same results.
    Terminal Complement Complex Tcc, supplied by Diatec Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/terminal complement complex tcc/product/Diatec Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    terminal complement complex tcc - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    Image Search Results


    C5b-9 levels of all mice administered with LMWCS-S-O and CS-P. The L-LMWCS-S-O, M-LMWCS-S-O and H-LMWCS-S-O groups were administered with 50, 150 and 450 mg/kg of LMWCS-S-O, respectively. The CS-P group was administered with 150 mg/kg of CS-P. The sham and model groups were administered with saline. Bar graphs present n ≥ 5. * p < 0.05 vs. the model; # p < 0.05 vs. the model.

    Journal: International Journal of Molecular Sciences

    Article Title: Preparation of Low Molecular Weight Chondroitin Sulfates, Screening of a High Anti-Complement Capacity of Low Molecular Weight Chondroitin Sulfate and Its Biological Activity Studies in Attenuating Osteoarthritis

    doi: 10.3390/ijms17101685

    Figure Lengend Snippet: C5b-9 levels of all mice administered with LMWCS-S-O and CS-P. The L-LMWCS-S-O, M-LMWCS-S-O and H-LMWCS-S-O groups were administered with 50, 150 and 450 mg/kg of LMWCS-S-O, respectively. The CS-P group was administered with 150 mg/kg of CS-P. The sham and model groups were administered with saline. Bar graphs present n ≥ 5. * p < 0.05 vs. the model; # p < 0.05 vs. the model.

    Article Snippet: Mouse terminal complement complex C5b-9 ELISA kit (Cusabio Biotech Co., Ltd., Wuhan, China) was used for the C5b-9 determination.

    Techniques:

    Direct and sandwich ELISA to determine mAb binding to human, monkey, rat and mouse C7. (A) Direct ELISA: plates were coated with human, monkey (cyno), rat or mouse C7; mAbs were tested in a dilution series (0–10 µg/ml). The graph shows representative binding with the 10 µg/ml capture. (B) Sandwich ELISA: the new mAbs were paired as capture and detect with human C7 used in a dilution series (0–5 µg/ml). The graph shows representative binding with 5 µg/ml C7. As a positive control, polyclonal anti-C7 (goat anti-C7) was used as capture with each of the mAb as detect; rat C7 captured on goat anti-C7 (goat anti-C7; rat C7) was also tested with the mAb as detect. (C) Sandwich ELISA to detect pre-formed TCC in activated NHS; TCC in activated NHS (and NRS for 2H2) was captured on aE11 anti-C9 and the novel mAbs and the positive control E2 anti-C8 mAb used to detect the TCC complex captured. (D) TCC complexes generated in NHS (or NRS for 2H2) in the presence of each of the new mAb (biotinylated) were captured on avidin-coated plates, then polyclonal antibodies against each of the terminal complement proteins used to test the presence of the respective components in the complex. The error bars are standard errors of triplicates. All experiments were repeated three times with the same results.

    Journal: Frontiers in Immunology

    Article Title: Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species

    doi: 10.3389/fimmu.2020.612402

    Figure Lengend Snippet: Direct and sandwich ELISA to determine mAb binding to human, monkey, rat and mouse C7. (A) Direct ELISA: plates were coated with human, monkey (cyno), rat or mouse C7; mAbs were tested in a dilution series (0–10 µg/ml). The graph shows representative binding with the 10 µg/ml capture. (B) Sandwich ELISA: the new mAbs were paired as capture and detect with human C7 used in a dilution series (0–5 µg/ml). The graph shows representative binding with 5 µg/ml C7. As a positive control, polyclonal anti-C7 (goat anti-C7) was used as capture with each of the mAb as detect; rat C7 captured on goat anti-C7 (goat anti-C7; rat C7) was also tested with the mAb as detect. (C) Sandwich ELISA to detect pre-formed TCC in activated NHS; TCC in activated NHS (and NRS for 2H2) was captured on aE11 anti-C9 and the novel mAbs and the positive control E2 anti-C8 mAb used to detect the TCC complex captured. (D) TCC complexes generated in NHS (or NRS for 2H2) in the presence of each of the new mAb (biotinylated) were captured on avidin-coated plates, then polyclonal antibodies against each of the terminal complement proteins used to test the presence of the respective components in the complex. The error bars are standard errors of triplicates. All experiments were repeated three times with the same results.

    Article Snippet: To characterize mAb binding to soluble terminal complement complexes (TCC), biotinylated mAbs (Pierce, #21327) were individually added to human or rat serum (100 µg/ml in 3 ml serum) and the mix activated via both classical and alternative pathways by incubation with Zymosan A (7 mg/ml; #21327, Pierce) and aggregated human IgG (1 mg/ml; in house) for 32 h at 37°C in a shaking water bath.

    Techniques: Sandwich ELISA, Binding Assay, Direct ELISA, Positive Control, Generated, Avidin-Biotin Assay

    Western blotting to detect C7 binding in serum and in TCC. (A) The human-specific mAbs 59E7 and 17E7 were used to probe WB of NHS (Hu) and Cynomolgus monkey (Mk) serum under non-reducing (NR) conditions. Secondary only control was included (2°). (B–E) The cross-species reactive mAbs 73D1 (B) , 3B11 (C) and 2H2 (D) and as control the polyclonal goat anti-C7 (E) were used to probe WB of NHS (Hu), monkey (Mk), mouse (Mo) and rat sera; purified human C7 was used as standard. All sera were run in duplicate. Polyclon3B11 (C) , 2H2 (D) , and positive control goat anti-C7 (E) . Results are representative of three independent experiments. M; protein molecular weight marker. (F–J) The novel mAbs were used to pull down complexes from activated serum; these were then run on WB under non-reduced and reduced conditions and probed with polyclonal antibodies against each of the terminal complement proteins. mAb 2H2 was used in rat (F) and human (G) serum; the other mAbs in human serum only (H–J) . The blots were cut into strips prior to probing to detect the individual terminal pathway proteins. Molecular weights used were: NR: C5, 190 kDa; C6, 105 kDa; C7, 95 kDa, C8αγ; 70 kDa; C9, 65 kDa. R: C6, 110 kDa; C7, 95 kDa; C5β, 75 kDa; C9, 70 kDa; C8α/β, 65 kDa; C8γ, 22 kDa. Results are representative of at least three analyses. M; protein molecular weight marker, 2°; secondary antibody. (K) The novel mAbs 17E7, 59E7 and 73D1 were separately immobilized on mouse IgG capture sensor chips (GE Healthcare, # BR-1008-38) and mAb 3B11 (IgM) on protein L Series S sensor chip (GE Healthcare #29-2051-38) at approximately 60 RU. Human, rat or mouse C7 was flowed in HEPES-buffered saline (HBS) in a dilution range of 66 to 8 nM and interactions with the immobilized mAbs were analyzed. Sensorgrams were collected and KDs were calculated using the Langmuir 1: 1 binding model with RI values set to zero. Representative sensorgrams for 17E7 and 59E7 binding of human C7 are shown with raw data in colored lines and fitted data in dotted line (average of 3); all binding data and analyses are included in <xref ref-type= Table 2 . The sensorgrams of clones 3B11 and 73D1 are included in Supplementary. The SPR analysis was performed in an automated manner using T200 Biacore Evaluation Software version 2 (GE Healthcare). " width="100%" height="100%">

    Journal: Frontiers in Immunology

    Article Title: Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species

    doi: 10.3389/fimmu.2020.612402

    Figure Lengend Snippet: Western blotting to detect C7 binding in serum and in TCC. (A) The human-specific mAbs 59E7 and 17E7 were used to probe WB of NHS (Hu) and Cynomolgus monkey (Mk) serum under non-reducing (NR) conditions. Secondary only control was included (2°). (B–E) The cross-species reactive mAbs 73D1 (B) , 3B11 (C) and 2H2 (D) and as control the polyclonal goat anti-C7 (E) were used to probe WB of NHS (Hu), monkey (Mk), mouse (Mo) and rat sera; purified human C7 was used as standard. All sera were run in duplicate. Polyclon3B11 (C) , 2H2 (D) , and positive control goat anti-C7 (E) . Results are representative of three independent experiments. M; protein molecular weight marker. (F–J) The novel mAbs were used to pull down complexes from activated serum; these were then run on WB under non-reduced and reduced conditions and probed with polyclonal antibodies against each of the terminal complement proteins. mAb 2H2 was used in rat (F) and human (G) serum; the other mAbs in human serum only (H–J) . The blots were cut into strips prior to probing to detect the individual terminal pathway proteins. Molecular weights used were: NR: C5, 190 kDa; C6, 105 kDa; C7, 95 kDa, C8αγ; 70 kDa; C9, 65 kDa. R: C6, 110 kDa; C7, 95 kDa; C5β, 75 kDa; C9, 70 kDa; C8α/β, 65 kDa; C8γ, 22 kDa. Results are representative of at least three analyses. M; protein molecular weight marker, 2°; secondary antibody. (K) The novel mAbs 17E7, 59E7 and 73D1 were separately immobilized on mouse IgG capture sensor chips (GE Healthcare, # BR-1008-38) and mAb 3B11 (IgM) on protein L Series S sensor chip (GE Healthcare #29-2051-38) at approximately 60 RU. Human, rat or mouse C7 was flowed in HEPES-buffered saline (HBS) in a dilution range of 66 to 8 nM and interactions with the immobilized mAbs were analyzed. Sensorgrams were collected and KDs were calculated using the Langmuir 1: 1 binding model with RI values set to zero. Representative sensorgrams for 17E7 and 59E7 binding of human C7 are shown with raw data in colored lines and fitted data in dotted line (average of 3); all binding data and analyses are included in Table 2 . The sensorgrams of clones 3B11 and 73D1 are included in Supplementary. The SPR analysis was performed in an automated manner using T200 Biacore Evaluation Software version 2 (GE Healthcare).

    Article Snippet: To characterize mAb binding to soluble terminal complement complexes (TCC), biotinylated mAbs (Pierce, #21327) were individually added to human or rat serum (100 µg/ml in 3 ml serum) and the mix activated via both classical and alternative pathways by incubation with Zymosan A (7 mg/ml; #21327, Pierce) and aggregated human IgG (1 mg/ml; in house) for 32 h at 37°C in a shaking water bath.

    Techniques: Western Blot, Binding Assay, Purification, Positive Control, Molecular Weight, Marker, Clone Assay, Software